Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can a new lens design improve overnight vision correction?

NCT ID NCT07751172

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 07, 2026 · Last updated Aug 12, 2026 · Updated 2 times

Summary

This trial evaluates Paragon CRT contact lenses with a 5mm optic zone diameter, worn overnight to temporarily reshape the cornea and correct myopia and astigmatism. Participants aged 6 to 35 will wear the lenses daily for a short period, and their comfort and visual performance will be assessed. The study aims to see if this lens design provides a comfortable and effective alternative to traditional glasses or daytime contacts.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Paragon CRT orthokeratology contact lenses with a 5mm optic zone diameter
What this could lead to
If successful, this could lead to more comfortable and effective overnight contact lenses for correcting nearsightedness and astigmatism.
What could go wrong
The trial is relatively small and early, and results may not apply to all lens wearers. There is also a risk of discomfort or other lens-related issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 70 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2026

An estimate. Start dates often move.

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

7 to 35 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: A person is eligible for inclusion in the study if they: 1. Are 6- 35 years of age 2. If under 18 years old they are accompanied by a parent or legal guardian who is able to read, understand and sign the parental information and permission document 3. Have had a self-reported visual exam in the last two years 4. Are able to read (or be read to), understand and sign the assent document if under 18 years old or are able to read, understand and sign the consent document if aged 18 or older 5. Are willing to comply with the wear schedule (approximately 8 hours per night for every night, while sleeping) 6. Are willing to comply with the visit schedule 7. Have a refractive spherical component of their prescription between -0.50 and up to -6.00 diopters (inclusive) AND a refractive cylinder of no more than -1.75 diopters 8. Have a refractive spherical component ≥ cylinder component 9. Have a minimum visual acuity of +0.20 logMAR with each eye, when refracted at the Screening visit 10. Have clear corneas and no active ocular disease. 11. Have no medication, medical condition, or ocular conditions that contraindicate contact lens wear OR are expected to affect lens comfort or vision across the 1-month study duration, in the opinion of the investigator 12. Can be shown to have stable keratometry for at least the previous 1 month, if they have previously worn orthokeratology lenses. Exclusion Criteria: 1. Present at screening visit with the presence of ocular or systemic disease or report the use medications which might interfere with orthokeratology contact lens wear, such as keratoconus, diabetes mellitus, steroid eye drops 2. Have a post-treatment predicted flat K value ≤38.00D (e.g. Patient baseline flat keratometry value = 40.00, patient has 2.00D of myopic refractive error. 40.00-2.00= 38.00D) 3. Have a known sensitivity to the diagnostic sodium fluorescein to be used in the study 4. Are pregnant, planning a pregnancy or lactating 5. Have amblyopia 6. Have presbyopia or has dependence on spectacles for near work over the contact lenses 7. Present at screening visit with the presence of clinically significant (grade ≥3; ISO scale) anterior segment abnormalities. 8. Present at screening visit with slit lamp findings that would contraindicate orthokeratology contact lens wear such as: 1\. Pathological dry eye or associated findings 2. Pterygium, pinguecula, or corneal scars within the visual axis 3. Neovascularization \> 0.75 mm from of the limbus 4. Giant papillary conjunctivitis (GPC) worse than grade 1 5. Anterior uveitis or iritis (past or present) 6. Seborrheic eczema, Seborrheic conjunctivitis 7. History of corneal ulcers or fungal infections 8. Poor personal hygiene 9. Aphakia

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Astigmatism are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    3 sites in 2 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Bellaire Family Eye Care

    Bellaire, Texas, 77401, United States

  • Complutense University of Madrid Av.

    Madrid, Moncloa - Aravaca,, 28040, Spain

  • Treehouse Eyes Pleasanton Center

    Pleasanton, California, 94588, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.